Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by striking a broad pact that positions Pfizer to leverage Chi ...

Pfizer unveiled a multi-drug R&D collaboration with Innovent Biologics, making it the latest big pharma company to reach a ...

One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale and steady cash flow.

Pfizer has entered a license agreement with Chai Discovery, a company engineering AI models to discover new molecules.

Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies. Now it’s in talks ...

Involving up to 12 antibody drugs, the alliance is the latest broad partnership between Chinese biotech and a multinational pharmaceutical company.

Pfizer $4.9 billion cash acquisition of Metsera, a clinical-stage biotech focused on next-generation obesity drugs, is more than another high-profile deal in pharma’s dealmaking spree. It signals a ...

Connecticut-based Pfizer Inc. said Thursday that it has completed the successful acquisition of Metsera, Inc., which is “a clinical-stage biopharmaceutical company accelerating the next generation of ...

As noted, Merck and Pfizer are both large pharmaceutical companies. Making and selling drugs is complex, expensive, and competitive. There are massive research and development costs involved in ...